Analyst Ratings For NASDAQ:SGEN – Seattle Genetics (NASDAQ:SGEN)
Today, HC Wainwright reiterated its Buy rating on NASDAQ:SGEN – Seattle Genetics (NASDAQ:SGEN).
Some recent analyst ratings include
- 6/5/2018-HC Wainwright Reiterated Rating of Buy.
- 5/17/2018-Cann Reiterated Rating of Hold.
- 3/20/2018-Royal Bank of Canada Reiterated Rating of Buy.
- 3/20/2018-Barclays initiated coverage with a Overweight ➝ Overweight rating.
- 3/13/2018-Cowen Reiterated Rating of Hold.
- On 5/31/2018 Vaughn B. Himes, Insider, sold 5,000 with an average share price of $58.47 per share and the total transaction amounting to $292,350.00.
- On 5/9/2018 Clay B. Siegall, CEO, sold 18,832 with an average share price of $54.97 per share and the total transaction amounting to $1,035,195.04.
- On 5/9/2018 Darren S. Cline, EVP, sold 9,000 with an average share price of $55.33 per share and the total transaction amounting to $497,970.00.
- On 5/8/2018 Bros. Advisors Lp Baker, Director, bought 460,651 with an average share price of $53.34 per share and the total transaction amounting to $24,571,124.34.
- On 5/4/2018 Bros. Advisors Lp Baker, Director, bought 204,537 with an average share price of $52.68 per share and the total transaction amounting to $10,775,009.16.
- On 5/3/2018 Darren S. Cline, EVP, sold 4,000 with an average share price of $53.81 per share and the total transaction amounting to $215,240.00.
- On 5/1/2018 Bros. Advisors Lp Baker, Director, bought 306,917 with an average share price of $51.36 per share and the total transaction amounting to $15,763,257.12.
Recent Trading Activity for NASDAQ:SGEN – Seattle Genetics (NASDAQ:SGEN)
Shares of NASDAQ:SGEN – Seattle Genetics closed the previous trading session at 62.02 up +0.51 0.83% with 61.459999084472656 shares trading hands.